From clinical trials to real-world evidence: Tofacitinib in the treatment of rheumatoid arthritis

20 Nov 2020
Janus kinase inhibitors (JAKIs) have emerged as an effective class of therapy for rheumatoid arthritis (RA).1 At the EULAR virtual symposium, a group of specialists discussed recent updates on tofacitinib (Xeljanz®, Pfizer) – the first-in-class JAKI for the treatment of RA.

Related MIMS Drugs

Editor's Recommendations